8329 (8329) Fair Value & Analysis

Healthcare · Market cap HK$181M

8 8329 8329 · HK

PriceHK$0.0980

Fair ValueHK$0.0890

Upside-9.2%

Quality52/100

Watch 8329 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$0.0648 – HK$0.1140

Fair value as of: Jul 3, 2026

From 9 valuation models · updated today

Share price −11.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.0980 – HK$0.1880 · fair‑value band HK$0.0648 – HK$0.1140 · the HK$0.0980 price screens above the HK$0.0890 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8329 (8329) currently trades at HK$0.0980, while our model-based Fair Value estimate is HK$0.0890 — implying the stock looks roughly 9.2% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 8329 generated revenue of HK$972M at a net margin of -4.2%. Revenue declined 4.2% year over year. It earns a return on equity of -6.1%. The balance sheet holds a net cash position of HK$126M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$972M

Revenue growth (YoY) -4.2%

Net margin -4.2%

Return on equity -6.1%

Free cash flow HK$125M FY2025

Operating margin -1.1%

More key figures

EPS (TTM) HK$0.0100

EPS growth (YoY) -48.8%

Net cash HK$126M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

8329 reported revenue of HK$972M in FY2025 versus HK$839M in FY2021, a compound +3.8%/yr. Reported net income was −HK$40.7M in FY2025.

Revenue +3.8%/yr

FY21 HK$839M

FY22 HK$987M

FY23 HK$1.1B

FY24 HK$1.0B

FY25 HK$972M

Net income

FY21 HK$36.0M

FY22 HK$54.3M

FY23 HK$24.1M

FY24 HK$25.0M

FY25 −HK$40.7M

Is 8329 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8329 (8329) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$0.0890 versus a price of HK$0.0980 — about −9% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 8329?

Our model-based fair value for 8329 is HK$0.0890 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$0.0980.

What is the quality score of 8329?

8329 has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8329 (8329)?

8329 reported trailing-twelve-month revenue of about HK$972M (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 8329?

The net profit margin of 8329 is about -4.2%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.